174 related articles for article (PubMed ID: 25741889)
1. Peptide-nanoparticle ligation mediated by cutinase fusion for the development of cancer cell-targeted nanoconjugates.
Galbiati E; Cassani M; Verderio P; Martegani E; Colombo M; Tortora P; Mazzucchelli S; Prosperi D
Bioconjug Chem; 2015 Apr; 26(4):680-9. PubMed ID: 25741889
[TBL] [Abstract][Full Text] [Related]
2. Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
Hansen L; Larsen EK; Nielsen EH; Iversen F; Liu Z; Thomsen K; Pedersen M; Skrydstrup T; Nielsen NC; Ploug M; Kjems J
Nanoscale; 2013 Sep; 5(17):8192-201. PubMed ID: 23835641
[TBL] [Abstract][Full Text] [Related]
3. Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.
Wang M; Löwik DW; Miller AD; Thanou M
Bioconjug Chem; 2009 Jan; 20(1):32-40. PubMed ID: 19099499
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
5. Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles.
Wang M; Miller AD; Thanou M
J Drug Target; 2013 Aug; 21(7):684-92. PubMed ID: 23773028
[TBL] [Abstract][Full Text] [Related]
6. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Abdalla MO; Karna P; Sajja HK; Mao H; Yates C; Turner T; Aneja R
J Control Release; 2011 Feb; 149(3):314-22. PubMed ID: 21047537
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release.
Li S; Yuan C; Chen J; Chen D; Chen Z; Chen W; Yan S; Hu P; Xue J; Li R; Zheng K; Huang M
Theranostics; 2019; 9(3):884-899. PubMed ID: 30809315
[TBL] [Abstract][Full Text] [Related]
8. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery.
Chen Z; Li Z; Lin Y; Yin M; Ren J; Qu X
Chemistry; 2013 Jan; 19(5):1778-83. PubMed ID: 23303570
[TBL] [Abstract][Full Text] [Related]
9. Expression of Cellulolytic Enzyme as a Fusion Protein That Reacts Specifically With a Polymeric Scaffold.
Katyal P; Yang Y; Vinogradova O; Lin Y
Methods Enzymol; 2017; 590():259-276. PubMed ID: 28411640
[TBL] [Abstract][Full Text] [Related]
10. Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Shahdeo D; Kesarwani V; Suhag D; Ahmed J; Alshehri SM; Gandhi S
Carbohydr Polym; 2021 Aug; 266():118138. PubMed ID: 34044952
[TBL] [Abstract][Full Text] [Related]
11. Protein oriented ligation on nanoparticles exploiting O6-alkylguanine-DNA transferase (SNAP) genetically encoded fusion.
Colombo M; Mazzucchelli S; Montenegro JM; Galbiati E; Corsi F; Parak WJ; Prosperi D
Small; 2012 May; 8(10):1492-7. PubMed ID: 22431243
[TBL] [Abstract][Full Text] [Related]
12. Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.
Ahmed MSU; Salam AB; Yates C; Willian K; Jaynes J; Turner T; Abdalla MO
Int J Nanomedicine; 2017; 12():6973-6984. PubMed ID: 29033565
[TBL] [Abstract][Full Text] [Related]
13. Biotechnological approaches toward nanoparticle biofunctionalization.
Avvakumova S; Colombo M; Tortora P; Prosperi D
Trends Biotechnol; 2014 Jan; 32(1):11-20. PubMed ID: 24182737
[TBL] [Abstract][Full Text] [Related]
14. Development of U11-functionalized gold nanoparticles for selective targeting of urokinase plasminogen activator receptor-positive breast cancer cells.
Avvakumova S; Galbiati E; Pandolfi L; Mazzucchelli S; Cassani M; Gori A; Longhi R; Prosperi D
Bioconjug Chem; 2014 Aug; 25(8):1381-6. PubMed ID: 25080049
[TBL] [Abstract][Full Text] [Related]
15. Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands.
Hodneland CD; Lee YS; Min DH; Mrksich M
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5048-52. PubMed ID: 11959956
[TBL] [Abstract][Full Text] [Related]
16. Peptide-mediated cancer targeting of nanoconjugates.
Raha S; Paunesku T; Woloschak G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(3):269-81. PubMed ID: 21046660
[TBL] [Abstract][Full Text] [Related]
17. Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy.
Chang Y; Yao S; Chen Y; Huang J; Wu A; Zhang M; Xu F; Li F; Huang Y
Nanoscale; 2019 Jan; 11(2):611-621. PubMed ID: 30556550
[TBL] [Abstract][Full Text] [Related]
18. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
[TBL] [Abstract][Full Text] [Related]
19. Dendritic effect of ligand-coated nanoparticles: enhanced apoptotic activity of silica-berberine nanoconjugates.
Halimani M; Chandran SP; Kashyap S; Jadhav VM; Prasad BL; Hotha S; Maiti S
Langmuir; 2009 Feb; 25(4):2339-47. PubMed ID: 19146398
[TBL] [Abstract][Full Text] [Related]
20. "Blind" targeting in action: From phage display to breast cancer cell targeting with peptide-gold nanoconjugates.
Galbiati E; Gambini L; Civitarese V; Bellini M; Ambrosini D; Allevi R; Avvakumova S; Romeo S; Prosperi D
Pharmacol Res; 2016 Sep; 111():155-162. PubMed ID: 27293049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
